COMP <GO>
UNH vs CVS // GROSS PROFIT MARGIN
UnitedHealth Group Incorporated (NYSE) VS. CVS Health Corporation (NYSE) • 15-METRIC TALLY: UNH 9
— CVS 4
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
gross-margins
88.57%
LAST: $90.25 (-0.09%) • MKT CAP: $115.53B
gross-margins
45.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UNH VS. CVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UNH | CVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 88.57% | 45.00% | +43.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.47% | 2.60% | +8.87 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.4x | 25.7x | -9.25 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 6.48% | 6.76% | -0.28 | CVS | /fcf-yield <GO> |
| Operating Margin | 4.82% | 1.20% | +3.62 | UNH | /operating-margins <GO> |
| Net Profit Margin | 3.14% | 0.40% | +2.74 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 6.46% | 7.80% | -1.34 | CVS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.28% | 2.94% | -0.66 | CVS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.12 | 2.31 | +0.81 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.74% | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.2 | 47.8 | +11.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.33 | 0.88 | -0.55 | CVS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.7x | 60.7x | -42.96 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $368.83B | $115.53B | $253.30B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UNH REV | CVS REV | UNH GROSS % | CVS GROSS % | UNH FCF | CVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $447.57B | $402.07B | 88.7% | 45.0% | $16.07B | $7.81B |
| FY 2024 | $400.28B | $372.81B | 88.3% | 44.7% | $20.70B | $6.33B |
| FY 2023 | $371.62B | $357.78B | 89.6% | — | $25.68B | -$2.67B |
| FY 2022 | $324.16B | — | 89.6% | — | $23.40B | — |
| FY 2021 | $287.60B | — | 89.2% | — | $19.89B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UNH // BETA 0.33
CVS // BETA 0.88